maxim lowered the price target on sientra inc nasdaq sien to 7 from 13 but kept a buy rating on the stock   analyst anthony vendetti notes that the companys q4 revenue was inline with its preannouncement in january but gross margin was below expectations   vendetti adds that the lower price target also reflects industrywide compression though he remains positive on sientras abovepeer growth in the breast products market stifel has also lowered the price target on sientra to 7 from 11 and with buy rating unchanged   analyst jonathan block says that though initial 2022 revenue guidance is slightly below his estimate and the street view he believes management is taking a conservative approach   block added that he likes the strategic direction that sientra is headed the company focuses on the longterm opportunity in the reconstruction market where he notes that pricing is more favorable relative to augmentation   earnings sientra reported q4 fy21 sales of 226 million 266 yy beating the consensus of 2148 million   it reported eps loss of 027 down from 040 a year ago and missing the consensus of 019   guidance for fy22 the company expects sales of 93 million  97 million versus the consensus of 9601 million   sientra will market its breast implants in canada through its local partner kai aesthetic   price action sien shares are up 407 at 256 during the market session on the last check thursday